Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02647320 · ClinicalTrials.gov registry record · Phase 2
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 298
- Enrollment target
NCT02647320 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 298 participants.
The verdict
NCT02647320, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 298 participants
- Enrollment target
Study Summary
The hypothesis of this Phase 2, 12-week study, is that DS-8500a will improve glycemic control relative to placebo, based on changes in HbA1c, with acceptable safety and tolerability, in patients with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin.
Interventions
- DRUG Placebo Tablet
- DRUG Placebo Capsule
- DRUG Sitagliptin 100 mg
- DRUG DS-8500a 25mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02647320
The ClinicalTrials.gov registry entry for NCT02647320 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo Tablet is the first listed.
NCT02647320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02647320 about?
NCT02647320 is a clinical study titled "12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin". The hypothesis of this Phase 2, 12-week study, is that DS-8500a will improve glycemic control relative to placebo, based on changes in HbA1c, with acceptable safety and tolerability, in patients with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin.
What is the current status of trial NCT02647320?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 298 participants. The study started on 2016-01. Estimated completion is 2017-01-31.
What interventions are being tested in trial NCT02647320?
The interventions under investigation include: Placebo Tablet (DRUG), Placebo Capsule (DRUG), Sitagliptin 100 mg (DRUG), DS-8500a 25mg (DRUG).
Who is sponsoring clinical trial NCT02647320?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.